First dose: dosing begins in the first human trial of UQ's COVID-19 vaccine

13 Jul 2020

The next critical phase for The University of Queensland’s COVID-19 vaccine is underway – with the research effort moving out of the lab and into human trials.

Healthy adult volunteers have received the first dose of the vaccine at the Brisbane clinic of phase 1 clinical trials specialist, Nucleus Network. 

(L-R) Professor Trent Munro, Professor Paul Young, and Associate Professor Keith Chappell

UQ vaccine project co-leader Professor Paul Young said the first human trial was about evaluating the safety of the vaccine and the immune response it generates in a group of healthy volunteers.

UQ was tasked by the Coalition for Epidemic Preparedness Innovations (CEPI) to develop a rapid response vaccine against the novel coronavirus in January, supported by an initial investment of up to US$4.5 million. 

The clinical batch of vaccine for use in the trial was manufactured in a close partnership between UQ and researchers at CSIRO’s advanced biologics production facility in Melbourne, with technical assistance from Australian biotech company CSL, Brisbane based Patheon and the global biotech company Cytiva (formerly GE Life Sciences).

Read full story on UQ News - stories